• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Cell & Gene Therapy

Collage poster study of businessmen picture chart arrow goes up
Marketing

Novartis, Sarepta tipped to drive genomic therapy sales boom

GlobalData tipped the market to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta’s Elevidys and Novartis’ Zolgensma.
Nick Paul Taylor May 15, 2025 12:18pm
increase

Bluebird investor reluctance pays off with better buyout offer

May 14, 2025 10:40am
warning

Bluebird warns of potential bankruptcy amid buyout delay

May 13, 2025 9:56am
pause button on blue background

Sarepta sees delays in treatment after Elevidys death report

May 7, 2025 8:03am
Gene

As Pfizer bows out, CSL keeps hemophilia gene therapy hopes alive

Apr 11, 2025 10:32am
Novartis

Novartis unveils $23B investment to beef up US manufacturing, R&D

Apr 10, 2025 3:18pm
More News

AmplifyBio shutters amid tough cell and gene therapy market

Apr 7, 2025 10:38am

FDA turmoil compounds challenges for cell and gene therapy field

Apr 2, 2025 3:16pm

Artis BioSolutions launches with acquisition of Landmark Bio

Apr 2, 2025 10:22am

CBER chief Peter Marks resigns from FDA

Mar 31, 2025 10:50am
See more stories

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings